TGR5 is Essential for Bile Acid‐Dependent Cholangiocyte Proliferation In Vivo and In Vitro
10.1136/gutjnl-2015-309458 · doi-reference
Role of the G Protein‐Coupled Bile Acid Receptor TGR5 in Liver Damage
10.1159/000450917 · doi-reference
The Pathophysiological Function of Non‐Gastrointestinal Farnesoid X Receptor
10.1016/j.pharmthera.2021.107867 · doi-reference
Genome‐Wide Tissue‐Specific Farnesoid X Receptor Binding in Mouse Liver and Intestine
10.1002/hep.23450 · doi-reference
Crosstalk Between Bile Acids and Intestinal Epithelium: Multidimensional Roles of Farnesoid X Receptor and Takeda G Protein Receptor 5
10.3390/ijms26094240 · doi-reference
The Role of Bile Salts in Liver Regeneration
10.1007/s12072-016-9723-8 · doi-reference
Bile Acid and Nonalcoholic Steatohepatitis: Molecular Insights and Therapeutic Targets
10.1016/j.jare.2023.06.009 · doi-reference
Gut Microbiome‐Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non‐Alcoholic Fatty Liver Disease
10.3389/fmicb.2021.761836 · doi-reference
Molecular Regulation of Bile Acid Homeostasis
10.1124/dmd.121.000643 · doi-reference
Bile Acid Signaling and Liver Regeneration
10.1016/j.bbagrm.2014.05.021 · doi-reference
The Gut Microbiome‐Bile Acid‐FXR Interplay: A Pivotal Axis in Metabolic and Gastrointestinal Diseases
10.1080/19490976.2026.2665890 · doi-reference
Activation of TGR5 in the Injured Nerve Site According to a Prevention Protocol Mitigates Partial Sciatic Nerve Ligation‐Induced Neuropathic Pain by Alleviating Neuroinflammation
10.1097/j.pain.0000000000003460 · doi-reference
Bile Acid Network and Vascular Calcification‐Associated Diseases: Unraveling the Intricate Connections and Therapeutic Potential
10.2147/cia.s431220 · doi-reference
Targeting of a Bile Acid Receptor, Takeda G Protein Receptor 5 [TGR5], by a Novel First‐in‐Class Competitive Antagonist, SBI‐364, Diminishes Hepatic and Renal Cystogenesis in Polycystic Liver and Kidney Disease
10.1021/acsptsci.4c00701 · doi-reference
Investigation of the Potential Role of TGR5 in Pancreatic Cancer by a Comprehensive Molecular Experiments and the Liquid Chromatography Mass Spectrometry (LC‐MS) Based Metabolomics
10.1007/s12672-022-00504-2 · doi-reference
Combinatorial Targeting of G‐Protein‐Coupled Bile Acid Receptor 1 and Cysteinyl Leukotriene Receptor 1 Reveals a Mechanistic Role for Bile Acids and Leukotrienes in Drug‐Induced Liver Injury
10.1002/hep.32787 · doi-reference
Discovery of 6alpha‐Ethyl‐23(S)‐Methylcholic Acid (S‐EMCA, INT‐777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity
10.1021/jm901390p · doi-reference
Structure‐Activity Relationship Study of Betulinic Acid, a Novel and Selective TGR5 Agonist, and Its Synthetic Derivatives: Potential Impact in Diabetes
10.1021/jm900872z · doi-reference
Pleiotropic Roles of Bile Acids in Metabolism
10.1016/j.cmet.2013.03.013 · doi-reference
Smoking as an Independent Risk Factor for Hepatocellular Carcinoma due to the α7‐Nachr Modulating the JAK2/STAT3 Signaling Axis
10.3390/jcm8091391 · doi-reference
Deficiency of G‐Protein‐Coupled Bile Acid Receptor Gpbar1 (TGR5) Enhances Chemically Induced Liver Carcinogenesis
10.1002/hep.26019 · doi-reference
Targeting TGR5 to Mitigate Liver Fibrosis: Inhibition of Hepatic Stellate Cell Activation Through Modulation of Mitochondrial Fission
10.1016/j.intimp.2024.112831 · doi-reference
Research Progress of Takeda G Protein‐Coupled Receptor 5 in Metabolic Syndrome
10.3390/molecules28155870 · doi-reference
Agonism for the Bile Acid Receptor GPBAR1 Reverses Liver and Vascular Damage in a Mouse Model of Steatohepatitis
10.1096/fj.201801373rr · doi-reference
Synergistic Anti‐Inflammatory Effect of Gut Microbiota and Lithocholic Acid on Liver Fibrosis
10.1007/s00011-022-01629-4 · doi-reference
Bile Acid Receptors in the Biliary Tree: TGR5 in Physiology and Disease
10.1016/j.bbadis.2017.08.021 · doi-reference
TGR5 Protects Against Cholestatic Liver Disease via Suppressing the NF‐κB Pathway and Activating the Nrf2/HO‐1 Pathway
10.21037/atm-21-2631 · doi-reference
Downregulation of TGR5 (GPBAR1) in Biliary Epithelial Cells Contributes to the Pathogenesis of Sclerosing Cholangitis
10.1016/j.jhep.2021.03.029 · doi-reference
The Crosstalk Between Gut Microbiota and Bile Acids Promotes the Development of Non‐Alcoholic Fatty Liver Disease
10.3390/microorganisms11082059 · doi-reference
Bile Acids Control Inflammation and Metabolic Disorder Through Inhibition of NLRP3 Inflammasome
10.1016/j.immuni.2016.10.009 · doi-reference
Modulation of Endothelium‐Derived Nitric Oxide Production and Activity by Taurine and Taurine‐Conjugated Bile Acids
10.1016/j.niox.2019.10.008 · doi-reference
Intestinal TGR5 Agonism Improves Hepatic Steatosis and Insulin Sensitivity in Western Diet‐Fed Mice
10.1152/ajpgi.00300.2018 · doi-reference
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD
10.1016/j.cgh.2023.12.009 · doi-reference
Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease
10.3390/nu13041104 · doi-reference
TGR5 Contributes to Glucoregulatory Improvements After Vertical Sleeve Gastrectomy in Mice
10.1136/gutjnl-2015-309871 · doi-reference
Targeted Disruption of G Protein‐Coupled Bile Acid Receptor 1 (Gpbar1/M‐Bar) in Mice
10.1677/joe.1.06546 · doi-reference
Bile Acid Binding Resin Improves Metabolic Control Through the Induction of Energy Expenditure
10.1371/journal.pone.0038286 · doi-reference
The Membrane‐Bound Bile Acid Receptor TGR5 Is Localized in the Epithelium of Human Gallbladders
10.1002/hep.23032 · doi-reference
The Cholangiocyte Glycocalyx Stabilizes the ‘Biliary HCO3 Umbrella’: An Integrated Line of Defense Against Toxic Bile Acids
10.1159/000371864 · doi-reference
Bile Acid‐Activated Receptors and the Regulation of Macrophages Function in Metabolic Disorders
10.1016/j.coph.2020.04.008 · doi-reference
